icon-folder.gif   Conference Reports for NATAP  
 
  HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis
December 8-12, 2013
Big Island, Hawaii
Back grey_arrow_rt.gif
 
 
 
A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Na´ve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results from the LONESTAR and ELECTRON Phase 2 Studies
 
 
  Reported by Jules Levin
HEP DART 2013, December 8-12, 2013, Big Island, HI, USA
 
AASLD: Gilead at AASLD: Sofosbuvir for GT 3, 2 and 1 - (11/18/13)
 
AASLD: Gilead at AASLD: 2 - (11/18/13)
 
AASLD: Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/02/13)
 
AASLD: BMS at AASLD - (11/18/13)
 
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013
 
Reported by Jules Levin
HEP DART 2013; Big Island, HI, USA
 
Eric Lawitz1,2, Catherine Stedman3, Fred F. Poordad1,2, Phillip S. Pang4, Xiao Ding4, Robert H. Hyland4, William T. Symonds4, Fernando E. Membreno1,2, Edward Gane5 1Texas Liver Institute, San Antonio, TX; 2University of Texas Health Science Center, San Antonio, TX; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand; 4Gilead Sciences, Inc, Foster City, CA; 5Auckland Clinical Studies, Auckland, New Zealand

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif

AASLD15.gif

AASLD16.gif

AASLD17.gif

AASLD18.gif

AASLD19.gif

AASLD20.gif